Vitruvias Therapeutics is voluntarily recalling one lot of Thyroid Tablets, USP 30 milligrams after testing found the product could be more potent than intended.
The consumer-level recall covers Lot 504950, which was distributed nationwide to Vitruvias Therapeutics’ direct accounts from Jan. 31 through Sept. 30, 2025, according to an Aug. 21 company announcement published by the FDA Aug. 24. The lot expires Sept. 30, 2026.
Taking superpotent Thyroid Tablets can cause symptoms of hyperthyroidism, including high blood pressure, chest pain, rapid heart rate and heart rhythm disturbances. Older adults, pregnant women and infants face greater risk, particularly with prolonged use.
Vitruvias Therapeutics has not received reports of adverse events related to the recalled lot. The company is notifying wholesalers to discontinue distribution and arranging for the recalled product to be destroyed. Patients taking tablets from Lot 504950 should not stop taking the medication without contacting their healthcare provider.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
